Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis And Fudan University To Set Up Cancer Research Lab

This article was originally published in PharmAsia News

Executive Summary

Novartis and Fudan University will jointly conduct research focusing on developing new approaches to understand the causes of cancer. The announcement was made at the groundbreaking ceremony of China Novartis Institutes For Biomedical Research in Shanghai that will accommodate more than 400 researchers in its phase I construction. Researchers from both Novartis Shanghai R&D Center and Fudan will work at a joint lab in the university campus, adopting innovative molecular genetics techniques to develop disease models for new target discovery for cancer therapy. The initial efforts will concentrate on research on liver cancer. (Click here for more - Chinese Language)
Advertisement

Related Content

Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 1 of 2)
Advertisement
UsernamePublicRestriction

Register

SC068183

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel